Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital
At the core of Quetzal's mission is a belief that cutting-edge science, guided by proven leadership, can redefine what's possible in treatment for conditions like Acute Promyelocytic Leukemia ('APL') and invasive infections. The company has formed around a multi-asset pipeline, initially including:
Built on Leadership Excellence
Quetzal is led by an executive team with deep expertise in drug development, clinical strategy, and operational execution. 'Our team was brought together by a shared conviction: that patients with rare diseases deserve the same urgency and innovation as those with more common conditions,' said Usman Ahmed, CEO. 'Quetzal Therapeutics is built to deliver on that promise with the right science, the right strategy, and the right people.'
Usman Ahmed, CEO & Chairman – A proven leader with over two decades of leadership in pharmaceuticals and start-up innovation. During his tenure at Nexus Pharmaceuticals, Usman led the execution of complex transactions, spearheaded operational improvements, and championed cost efficiencies in the highly specialized and challenging field of specialty and generic injectables.
Dr. Sridhar Desikan, Co-Founder & Chief Scientific Officer – An industry veteran with 28 years of experience in NCE and generics development. Sridhar began his career at Novartis Pharmaceuticals and subsequently worked at DuPont Pharma, Bristol-Myers Squibb, Dr. Reddy's, and most recently at Nexus Pharmaceuticals as Chief Scientific Officer. Sridhar holds a Ph.D. in Chemical Engineering and has accreditations from Harvard Medical School's HMX Pro program.
Sara Mathews, Vice President Program Leadership – With nearly 15 years of experience in the biotech industry, Sara is a seasoned asset leader with a proven track record of bringing cross-functional teams together and leading novel oncology therapeutics through global clinical programs from IND filing through late-stage development, filing preparation, and commercial launch planning.
Christina Liwski, General Counsel & CHRO – With over a decade of diverse and sophisticated legal experience, Christina brings deep legal acumen to the team. Christina's experience spans multiple practice areas, including transactions and litigation. She most recently served as Assistant General Counsel at Nexus Pharmaceuticals, LLC and is admitted to practice in Illinois, Massachusetts, and the United States District Court for the District of Massachusetts.
Guided by an Accomplished Board of Directors
The company's Board of Directors features industry leaders with a track record of building, funding, and guiding successful companies:
Aman Ahmed – With nearly a decade of experience in the pharmaceutical industry, Aman brings deep expertise in sales operations, DEA and FDA regulatory compliance, international sales, and therapeutic portfolio management.
Dr. Jonathan Cheng – Dr. Jonathan Cheng is a physician-scientist and oncology drug development expert with a distinguished career across both industry and academia. As Chief Medical Officer at Systimmune, he leads the clinical development of a diverse pipeline of novel therapeutics, including innovative antibody-drug conjugates (ADCs) and the company's first-in-class EGFR-HER3 bispecific ADC currently in Phase 3 trials.
Todd Chermak, R.Ph., Ph.D – Todd Chermak is a life sciences executive with 30 years of experience spanning the biopharmaceutical, diagnostics, and nutrition industries. He currently serves as Senior Vice President and Global Business Head of Immunology and Proteomics at CellCarta.
Mike Warmuth – Mike Warmuth is currently working on various Boards: for profit, academic, and not-for-profit. From 2018 to 2023 Mr. Warmuth worked for EW Healthcare as an Operating Partner in their New York office. Prior to EW, Mr. Warmuth spent 30 years at Abbott in various senior executive capacities, where he led multiple divisions and business units.
Strategic Talent Acquisition Partnership
Quetzal Therapeutics proudly acknowledges the role of Heidrick & Struggles, a premier global leadership advisory firm, in identifying and recruiting Dr. Jonathan Cheng to the company's Board of Directors. Their expertise and commitment to excellence were instrumental in securing a highly respected thought leader whose insight will help shape Quetzal's long-term scientific and clinical strategy.
For more information, please visit: www.quetzaltx.com
Media Contact:
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Potential Multi-Year Growth for Saia (SAIA) If Freight Industry Rebounds
The London Company, an investment management company, released 'The London Company SMID Cap Strategy' second quarter 2025 investor letter. A copy of the letter can be downloaded here. Following a downturn in Q1, U.S. stocks experienced a double-digit gain in Q2, amid volatility stemming from tariff news. A risk-on rally followed due to a temporary pause in tariff escalations, widespread optimism around enterprise AI, and a healthy earnings outlook. Against this backdrop, the portfolio fell 0.6% (-0.8% net) during the second quarter vs. an 8.6% increase in the Russell 2500 Index. Sector allocation contributed to the fund's performance in the quarter, while stock selection detracted. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, The London Company SMID Cap Strategy highlighted stocks such as Saia, Inc. (NASDAQ:SAIA). Saia, Inc. (NASDAQ:SAIA) is a North America-based transportation company. The one-month return of Saia, Inc. (NASDAQ:SAIA) was 9.19%, and its shares lost 23.58% of their value over the last 52 weeks. On July 28, 2025, Saia, Inc. (NASDAQ:SAIA) stock closed at $323.23 per share, with a market capitalization of $8.61 billion. The London Company SMID Cap Strategy stated the following regarding Saia, Inc. (NASDAQ:SAIA) in its second quarter 2025 investor letter: "Saia, Inc. (NASDAQ:SAIA) – SAIA remained weak this quarter as the lingering 'freight recession' drags on for almost its third year. We remain convicted in our ownership of SAIA due to its solid balance sheet and strong network growth plan. We believe the company could be a multi-year compounder, assuming the freight industry returns to normal demand patterns. A long line of trucks transporting goods across the open road, symbolizing the long-distance transportation services of the company. Saia, Inc. (NASDAQ:SAIA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held Saia, Inc. (NASDAQ:SAIA) at the end of the first quarter, compared to 31 in the previous quarter. In the second quarter of 2025, Saia, Inc. (NASDAQ:SAIA) announced revenue of $817 million, marking a 0.7% decrease compared to the same quarter last year. While we acknowledge the potential of Saia, Inc. (NASDAQ:SAIA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Saia, Inc. (NASDAQ:SAIA) and shared Polen US SMID Company Growth Strategy's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
The Hill
3 hours ago
- The Hill
Cutting animal testing will jeopardize human health
The Food and Drug Administration and National Institutes of Health held a joint workshop July 7 on reducing animal testing in research, strikingly announcing that 'NIH will no longer seek proposals exclusively for animal models.' This change follows the FDA's plan to phase out the requirement for animal testing of drugs, which marked the beginning of an overall shift away from animal research to what the new leadership refers to as 'more effective, human-relevant methods.' What this means is the FDA intends to allow new drugs to be trialed in people without prior animal tests, and that the NIH will restrict funding for the very kind of research that has led to transformative medical discoveries. As a biomedical researcher using mouse models and other tools to better understand and treat human disease, I am deeply concerned. Eliminating animal testing will make our drug supply less safe and set us back decades in making groundbreaking biomedical discoveries. Let's look first at drug regulation. Identifying potential new therapies first depends heavily on knowledge gained from preclinical studies in animals. These studies form the basis of biological discovery, including assessing a drug's relevance, safety and potential efficacy before it's ever given to humans. Without this critical step, discovering new drugs will be far more difficult to begin with and their effects far less predictable. Only after these initial studies do drugs move into clinical testing — involving progressively larger human cohorts across three phases before approval. Animal models are a crucial component of biomedical research because they allow us to test unpredictable biological effects between different organs and systems within a living body. For example, a cancer drug might successfully kill tumor cells in a dish, but in a whole organism, it could cause unexpected heart damage or trigger a harmful immune response affecting other organs. An animal test is the closest possible test of the utility and safety of any drug before it's given to humans. If drug developers are allowed to skip this step, it will mean that, in the near future, the first living body a new drug is ever tested in will be a human body. Researchers also use animals to understand diseases and develop completely new therapies. Laboratory mice, the most commonly used animal model, have been likened to the Rosetta Stone of immunology. Much of what we now know about the immune system has been deciphered through them. Think of immunotherapies for cancer, immunosuppressive drugs for autoimmune conditions, or treatments for allergies and infectious diseases. None of these life-saving medicines would exist today without decades of foundational research in animal models. Nearly half of NIH-funded grants involve animal use. So why would the world's largest public funder of biomedical research decide to make such drastic changes? The argument is that new human-based approaches can serve as a better alternative. These include lab-grown human models, computational tools and other approaches. And these can certainly complement animal models, as my colleagues and I have long worked toward. But it is premature to treat them as viable replacements. One of the main criticisms of animal research is that the findings don't always translate directly to humans. That is true, but there's little evidence that the proposed alternatives yield more reliable or predictive results. Instead of abandoning animal research, we should focus on improving existing models to better reflect human biology. And it's true that some mice need improving. For example, in 2006, a new drug that acts on immune cells passed through animal testing and reached the human clinical trial phase, yet it left six healthy volunteers in a critical condition. Researchers later realized that laboratory mice had less activated immune systems compared with adult humans, because the abnormally hygienic environment of the lab prevented proper immune growth. (Germs are actually essential in teaching the immune system how to protect us.) Researchers confirmed that adding mice from a pet-store (living under less sterile and more natural conditions with diverse germs) to the same cages as laboratory mice helped the latter's immune systems more closely resemble those of humans. When researchers tested the same drug from the 2006 trial in mice with more natural immune systems, they found that the mice experienced similar inflammatory complications. More recently, researchers using such mice were also able to better understand the causes of side effects from cancer immunotherapies. And work has been under way using these improved mice for many other studies that can advance human health. This discovery helped launch a whole new field, in which researchers like myself are working to improve mouse models and accelerate biomedical discoveries. After the announcement, the People for the Ethical Treatment of Animals called it a 'groundbreaking move' that is 'a crucial first step to modernizing science and sparing millions of animals from miserable lives and deaths in laboratories.' But it's possible to care for animals ethically without eliminating their scientific use. Indeed, the NIH has had animal welfare policies dating back to the beginning of the 1900s. And for at least a decade, all grant proposals have had to include consideration of alternative approaches, scientific justification of animal use and detailed protocols to minimize their distress. Institutions' protocols are also regularly reviewed for accreditation. We still need animal testing to find new treatments. Take the story of one-week-old baby KJ that was in the news in May. KJ was born with a severe genetic disorder that kills nearly half of affected babies in early life. But, through extensive medical efforts, which included the use of a mouse model modified with the diseased gene portion specific to KJ, a customized therapy was developed and successfully administered within eight months. The list of biomedical successes that used animal models spans centuries — from first defining the functions of the brain and heart, to the discovery of insulin, to the development of 'miracle' cancer drugs. Human health is a shared priority, and now more than ever, it demands meaningful collaboration between scientists and physicians, policymakers and the public to protect the research systems that have enabled medicine's greatest breakthroughs. To borrow the recent words of Nobel laureate Ardem Patapoutian, 'Now is the time for all of us to speak up — because protecting American science means protecting our future shared prosperity.' The FDA and NIH are welcoming public feedback on this and likely future workshops, and I urge everyone to make their voices heard. Anis Barmada is a biomedical researcher at Yale School of Medicine, P.D. Soros Fellow, and Public Voices Fellow of The OpEd Project. His research combines animal models with human-based and computational tools to better understand and treat human disease.
Business Wire
3 hours ago
- Business Wire
AQNEURSA ® (levacetylleucine) Recommended for EU Approval by the CHMP to Treat Niemann-Pick Disease Type C
AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc., a biopharmaceutical company focused on developing therapies for rare neurological diseases, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of AQNEURSA ® (levacetylleucine) for the treatment of Niemann-Pick disease type C (NPC). "This positive CHMP opinion represents another important milestone in expanding access to AQNEURSA to the global NPC community," said Dr. Marc Patterson, Chief Medical Officer of IntraBio. "The recommendation reflects the strength of our clinical data and the potential for AQNEURSA to be a foundational therapy for NPC, delivering meaningful benefits for patients. We are proud to work alongside the NPC community to bring this long-awaited treatment option to even more families.' NPC is a rare, inherited lysosomal disorder characterized by progressive neurological deterioration, leading to loss of motor function, difficulties with speech and swallowing, and cognitive decline. 3 NPC affects both children and adults, significantly impacting quality of life and daily functioning. 3,4 "For NPC families like mine, this positive opinion brings long-awaited hope for a treatment that can actually offer improvements," said Carmelo Fernández, President of Fundación Niemann-Pick de España. "We have waited years for a therapy that can make a meaningful difference in the lives of people with NPC, and today's announcement brings us one step closer." The positive CHMP's opinion is based on results from IntraBio's pivotal Phase III randomized, placebo-controlled, clinical trial (IB1001-301; NCT05163288), which evaluated the impact of AQNEURSA on neurological symptoms and functioning in pediatric and adult patients (n=60) with a confirmed diagnosis of NPC. AQNEURSA significantly improved neurological symptoms and functional abilities across its primary and all secondary endpoints within 12 weeks of treatment versus placebo, and was well tolerated throughout the development program. 1 The CHMP opinion was further supported by long-term extension phase data showing that treatment with AQNEURSA had disease-modifying and neuroprotective effects, helping to reverse disease progression over time. 2 Detailed results from the IB1001-301 trial were published in The New England Journal of Medicine in February 2024. 1 About AQNEURSA AQNEURSA was approved by the U.S. Food and Drug Administration (FDA) on 24 September 2024 for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. 5 Since approval in the U.S., AQNEURSA has experienced rapid adoption as a frontline therapy for NPC with continued growth in demand. IntraBio remains on track to proceed with additional global regulatory submissions for AQNEURSA in 2025 and beyond. IntraBio's Phase III Pivotal trial investigating N-Acetyl-L-Leucine (levacetylleucine) for Ataxia-Telangiectasia has completed recruitment in under two months, ultimately over-enrolling the trial by over 167%. Data readout is expected in Q1 of 2026. U.S. IMPORTANT SAFETY INFORMATION Embryo-Fetal Toxicity Based on findings from animal reproduction studies, AQNEURSA may cause embryo-fetal harm when administered during pregnancy. The decision to continue or discontinue AQNEURSA treatment during pregnancy should consider the female's need for AQNEURSA, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal disease. Pregnancy and Lactation For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment with AQNEURSA. Advise females of reproductive potential to use effective contraception during treatment with AQNEURSA and for 7 days after the last dose if AQNEURSA is discontinued. There are no data on the presence of levacetylleucine or its metabolites in either human or animal milk, the effects on the breastfed infant or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AQNEURSA and any potential adverse effects on the breastfed infant from levacetylleucine or from the underlying maternal condition. Adverse Reactions The most common adverse reactions (incidence ≥5% and greater than placebo) are abdominal pain, dysphagia, upper respiratory tract infections, and vomiting. Drug Interactions Avoid concomitant use of AQNEURSA with N-acetyl-DL-leucine or N-acetyl-D-leucine. The D-enantiomer, N-acetyl-D-leucine, competes with levacetylleucine for monocarboxylate transporter uptake, which may reduce the levacetylleucine efficacy. Monitor more frequently for P-gp substrate related adverse reactions when used concomitantly with AQNEURSA; AQNEURSA inhibits P-gp; however, the clinical significance of this finding has not been fully characterized. To report SUSPECTED ADVERSE REACTIONS, contact IntraBio Inc. at 1-833-306-9677 or FDA at 1-800-FDA-1088 or Please click here for Full Prescribing Information for AQNEURSA: About Niemann-Pick Disease Type C Niemann-Pick disease Type C (NPC) is a rare (1:100,000 live births), prematurely fatal, autosomal recessive, lysosomal storage disorder. 6 The disease presents with systemic, psychiatric, and neurological symptoms, including cerebellar ataxia. NPC is chronic and progressive in nature and is characterized by rapid degeneration of the cerebellum and major organ systems which severely impacts the quality of life. 3,4,7 About IB1001-301 IB1001-301 (NCT05163288) is a multinational, randomized, placebo-controlled, crossover trial that evaluates the safety and efficacy of IB1001 (AQNEURSA, levacetylleucine) in pediatric and adult patients with NPC. Patients aged 4 years and older were screened at trial sites in Australia, Europe, the United Kingdom, and the United States. Patients were assessed during a baseline period and then randomly assigned (1:1) to receive orally administered IB1001 or placebo for 12 weeks. At the end of the 12-week treatment period, patients crossed over and initiated therapy with the alternate study drug (IB1001 or placebo) over the subsequent 12-week period. Patients who completed the study had the option to participate in an open-label Extension Phase, with some patients having been dosed for over 5 years. About IntraBio IntraBio Inc. is a global biopharmaceutical company that develops and commercializes targeted therapies for rare and common neurological and neurodevelopmental diseases. IntraBio's platform technologies result from decades of research and collaboration with universities and institutions worldwide, and leverages the expertise of its scientific founders from the University of Oxford and the University of Munich. For more information about IntraBio, please visit the company's website at and follow on LinkedIn (@IntraBio-Inc). References 1. Bremova-Ertl T, et al. J Neurol. 2022;269(3):1651-1662 2. Patterson, Marc C., et al. "Disease-modifying, neuroprotective effect of N-acetyl-l-leucine in adult and pediatric patients with Niemann-Pick disease type C." Neurology 105.1 (2025): e213589. 3. Geberhiwot T, et al. Orphanet J of Rare Dis. 2018;13:50 4. Patterson MC, et al. Orphanet J Rare Dis. 2013;8:12; 3. NORD. NPC Signs & Symptoms. Published Dec 12, 2023. Accessed May 19, 2024. 5. AQNEURSA. Prescribing Information. IntraBio Inc 6. Burton BK, Ellis AG, Orr B, et al. Estimating the prevalence of Niemann-Pick disease type C (NPC) in the United States. Mol Genet Metab 7. Vanier MT. Orphanet J Rare Dis. 2010;5:16.
